PE20250833A1 - Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead - Google Patents
Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-teadInfo
- Publication number
- PE20250833A1 PE20250833A1 PE2024001455A PE2024001455A PE20250833A1 PE 20250833 A1 PE20250833 A1 PE 20250833A1 PE 2024001455 A PE2024001455 A PE 2024001455A PE 2024001455 A PE2024001455 A PE 2024001455A PE 20250833 A1 PE20250833 A1 PE 20250833A1
- Authority
- PE
- Peru
- Prior art keywords
- group
- tead
- yap
- taz
- tetrahydropyrazolopyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a unos compuestos de Formula I o un estereoisomero, tautomero, sal farmaceuticamente aceptable o solvato de estos, en donde Y, Y1 e Y3 son cada uno N, entre otros; Y2 es N, CH, entre otros; R1 se selecciona del grupo que consta de H, -C(=O)Z2 donde Z2 se selecciona independientemente del grupo que consta de alquinilo C2-C6, cicloalquilo C3-C6, entre otros; R2 se selecciona del grupo que consta de H, halogeno, entre otros; R4, R5, R8 y R9 se seleccionan independientemente del grupo que consta de hidrogeno y alquilo C1-C6; R6 se selecciona del grupo que consta de halogeno, -CH2-C(=O)OH, entre otros; R7 se selecciona del grupo que consta de H, entre otros. Tambien se refiere a una composicion farmaceutica que comprende dichos compuestos, o un estereoisomero, tautomero, sal farmaceuticamente aceptable o solvato de estos, y un portador farmaceuticamente aceptable; el uso del compuesto o la composicion farmaceutica para la prevencion o tratamiento de un trastorno mediado por activacion de YAP/TAZ-TEAD en un animal, mamifero o humano; y un metodo para la prevencion o tratamiento del trastorno en mencion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293538P | 2021-12-23 | 2021-12-23 | |
| PCT/US2022/082327 WO2023122783A2 (en) | 2021-12-23 | 2022-12-23 | Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250833A1 true PE20250833A1 (es) | 2025-03-21 |
Family
ID=86903815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001455A PE20250833A1 (es) | 2021-12-23 | 2022-12-23 | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230279016A1 (es) |
| EP (1) | EP4452254A4 (es) |
| JP (1) | JP2025501773A (es) |
| KR (1) | KR20240137563A (es) |
| CN (1) | CN118613257A (es) |
| AR (1) | AR128110A1 (es) |
| AU (1) | AU2022419653A1 (es) |
| CL (1) | CL2024001894A1 (es) |
| CO (1) | CO2024009582A2 (es) |
| IL (1) | IL313630A (es) |
| MX (1) | MX2024007929A (es) |
| PE (1) | PE20250833A1 (es) |
| TW (1) | TW202333679A (es) |
| WO (1) | WO2023122783A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025534549A (ja) | 2022-09-29 | 2025-10-16 | インシリコ メディシン アイピー リミテッド | Ｔｅａｄ阻害剤およびその使用の方法 |
| WO2025019604A2 (en) * | 2023-07-18 | 2025-01-23 | The General Hospital Corporation | Proteolysis targeting chimeras for treating neurodegeneration |
| WO2025088534A1 (en) * | 2023-10-27 | 2025-05-01 | Dong-A St Co., Ltd. | Bicyclic heterocycle compounds as tead inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3539961T3 (pl) * | 2015-06-29 | 2022-02-14 | Astrazeneca Ab | Policykliczne pochodne amidowe jako inhibitory CDK9 |
| CN112204029B (zh) * | 2018-05-31 | 2024-03-01 | 豪夫迈·罗氏有限公司 | 治疗性化合物 |
| AR123656A1 (es) * | 2020-09-30 | 2022-12-28 | Univ Leuven Kath | Derivados de 1,2,3,4-tetrahidroquinolina |
-
2022
- 2022-12-23 TW TW111149734A patent/TW202333679A/zh unknown
- 2022-12-23 MX MX2024007929A patent/MX2024007929A/es unknown
- 2022-12-23 WO PCT/US2022/082327 patent/WO2023122783A2/en not_active Ceased
- 2022-12-23 AU AU2022419653A patent/AU2022419653A1/en active Pending
- 2022-12-23 KR KR1020247023106A patent/KR20240137563A/ko active Pending
- 2022-12-23 CN CN202280090241.2A patent/CN118613257A/zh active Pending
- 2022-12-23 IL IL313630A patent/IL313630A/en unknown
- 2022-12-23 EP EP22912765.9A patent/EP4452254A4/en active Pending
- 2022-12-23 JP JP2024538715A patent/JP2025501773A/ja active Pending
- 2022-12-23 PE PE2024001455A patent/PE20250833A1/es unknown
- 2022-12-23 US US18/145,986 patent/US20230279016A1/en active Pending
- 2022-12-26 AR ARP220103591A patent/AR128110A1/es unknown
-
2024
- 2024-06-21 CL CL2024001894A patent/CL2024001894A1/es unknown
- 2024-07-19 CO CONC2024/0009582A patent/CO2024009582A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240137563A (ko) | 2024-09-20 |
| CL2024001894A1 (es) | 2024-12-06 |
| IL313630A (en) | 2024-08-01 |
| US20230279016A1 (en) | 2023-09-07 |
| CN118613257A (zh) | 2024-09-06 |
| EP4452254A4 (en) | 2025-12-31 |
| MX2024007929A (es) | 2024-09-10 |
| TW202333679A (zh) | 2023-09-01 |
| WO2023122783A2 (en) | 2023-06-29 |
| WO2023122783A3 (en) | 2023-08-24 |
| CO2024009582A2 (es) | 2024-10-21 |
| JP2025501773A (ja) | 2025-01-23 |
| EP4452254A2 (en) | 2024-10-30 |
| AU2022419653A1 (en) | 2024-07-18 |
| AR128110A1 (es) | 2024-03-27 |
| WO2023122783A8 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250833A1 (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20230673A1 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| PE20220133A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| CO2024017733A2 (es) | Inhibidores macrocíclicos de kras para el tratamiento de cáncer | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20221910A1 (es) | Derivados de pirazolilo utiles como agentes anticancerigenos | |
| PE20240775A1 (es) | Compuestos antivirales | |
| PE20252677A1 (es) | Amidas de azolipiridina piridazinona como inhibidores de sos1 | |
| PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
| PE20241129A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| PE20250155A1 (es) | Derivados de la urea que pueden ser utilizados para tratar el cancer | |
| PE20210140A1 (es) | Moduladores de la proteina reguladora de conductancia transmembrana de la fibrosis quistica y metodos de uso | |
| PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| PE20240691A1 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
| AR094550A1 (es) | Inhibidores de btk | |
| PE20240769A1 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| PE20212329A1 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer |